Trial Outcomes & Findings for Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF (NCT NCT01423851)
NCT ID: NCT01423851
Last Updated: 2022-03-09
Results Overview
AEs (non-serious, serious) as variables of safety and tolerability of NS-018 were assesed. The number of patients were presented as Overall summary of AEs including treatment-emergent AEs (TEAEs); Treatment-emergent SAEs; Drug-related TEAEs; Treatment-emergent AEs leading to permanent discontinuation of study drug; Hospitalization or prolongation of existing hospitalization; Death.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
77 participants
Primary outcome timeframe
From screening to until study discontinuation (approximate 8 years 10 months)
Results posted on
2022-03-09
Participant Flow
Subjects who met all the inclusion and none of the exclusion criteria were enrolled at 09 sites in the USA. The conduct of this study started on 02 June 2011 (the first patient screened) and the last patient last visit was on 22 April 2020. A total of 48 and 29 patients were enrolled during Phase 1 and Phase 2 of the study respectively. Participants could be reduced or escalated to the noted dose at physician discretion.
The screening period was from Day -14 to Day 0 for Phase I and Phase II. Informed consent form (ICF) was signed prior to screening procedures. All the study assessments were performed as per the schedule of assessment.
Participant milestones
| Measure |
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Whole Study
STARTED
|
3
|
3
|
3
|
6
|
3
|
3
|
3
|
8
|
8
|
8
|
29
|
|
Whole Study
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Whole Study
NOT COMPLETED
|
3
|
3
|
3
|
6
|
3
|
3
|
3
|
8
|
8
|
8
|
29
|
|
Dose Finding Period - Escalation
STARTED
|
0
|
1
|
4
|
4
|
0
|
0
|
2
|
0
|
1
|
0
|
0
|
|
Dose Finding Period - Escalation
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Dose Finding Period - Escalation
NOT COMPLETED
|
0
|
1
|
4
|
4
|
0
|
0
|
2
|
0
|
1
|
0
|
0
|
|
Dose Finding Period - Reduction
STARTED
|
0
|
0
|
3
|
5
|
1
|
2
|
8
|
0
|
3
|
0
|
0
|
|
Dose Finding Period - Reduction
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Dose Finding Period - Reduction
NOT COMPLETED
|
0
|
0
|
3
|
5
|
1
|
2
|
8
|
0
|
3
|
0
|
0
|
Reasons for withdrawal
| Measure |
Part 1: 75 mg QD
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Whole Study
Disease progression
|
2
|
1
|
1
|
4
|
1
|
3
|
1
|
4
|
0
|
2
|
10
|
|
Whole Study
Physician Decision
|
0
|
1
|
2
|
0
|
2
|
0
|
2
|
1
|
3
|
4
|
12
|
|
Whole Study
Withdrawal by Subject
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
4
|
|
Whole Study
Adverse Event
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
3
|
3
|
2
|
3
|
Baseline Characteristics
For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
Baseline characteristics by cohort
| Measure |
Part 1: 75 mg QD
n=3 Participants
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=3 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg QD
n=6 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=3 Participants
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=3 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=3 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=8 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=8 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=8 Participants
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=29 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Total
n=77 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
Part 1
|
72.7 Years
STANDARD_DEVIATION 1.5 • n=3 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
70.3 Years
STANDARD_DEVIATION 14.8 • n=3 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
63.7 Years
STANDARD_DEVIATION 12.9 • n=3 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
67.3 Years
STANDARD_DEVIATION 9.4 • n=6 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
67.3 Years
STANDARD_DEVIATION 3.8 • n=3 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
65.0 Years
STANDARD_DEVIATION 8.9 • n=3 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
69.0 Years
STANDARD_DEVIATION 3.6 • n=3 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
63.0 Years
STANDARD_DEVIATION 11.8 • n=8 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
62.4 Years
STANDARD_DEVIATION 11.9 • n=8 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
69.3 Years
STANDARD_DEVIATION 7.7 • n=8 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
—
|
66.4 Years
STANDARD_DEVIATION 9.6 • n=48 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
|
Age, Continuous
Part 2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
67.2 Years
STANDARD_DEVIATION 9.3 • n=29 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
67.2 Years
STANDARD_DEVIATION 9.3 • n=29 Participants • For Age continuous, Part 1 and Part 2 data are presented in different rows (48+29=77).
|
|
Sex: Female, Male
Female
|
0 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=6 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
3 Participants
n=8 Participants
|
6 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
14 Participants
n=29 Participants
|
33 Participants
n=77 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=3 Participants
|
3 Participants
n=6 Participants
|
1 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=3 Participants
|
5 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
5 Participants
n=8 Participants
|
15 Participants
n=29 Participants
|
44 Participants
n=77 Participants
|
|
Race/Ethnicity, Customized
White/Caucasian
|
3 Participants
n=3 Participants
|
3 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
6 Participants
n=6 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=3 Participants
|
2 Participants
n=3 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
8 Participants
n=8 Participants
|
26 Participants
n=29 Participants
|
71 Participants
n=77 Participants
|
|
Race/Ethnicity, Customized
Black/African Heritage
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=29 Participants
|
3 Participants
n=77 Participants
|
|
Race/Ethnicity, Customized
Asian/Oriental
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=29 Participants
|
2 Participants
n=77 Participants
|
|
Race/Ethnicity, Customized
Other
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=29 Participants
|
1 Participants
n=77 Participants
|
PRIMARY outcome
Timeframe: From screening to until study discontinuation (approximate 8 years 10 months)Population: The safety population included all patients who received at least 1 dose of study drug. NS-018-101 study was dose-finding study, Principal investigator (PI) could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
AEs (non-serious, serious) as variables of safety and tolerability of NS-018 were assesed. The number of patients were presented as Overall summary of AEs including treatment-emergent AEs (TEAEs); Treatment-emergent SAEs; Drug-related TEAEs; Treatment-emergent AEs leading to permanent discontinuation of study drug; Hospitalization or prolongation of existing hospitalization; Death.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=15 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=4 Participants
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=5 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=13 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=8 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=12 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=8 Participants
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=29 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=3 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=4 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=10 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
Not TEAE
|
0 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
6 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
Any AE
|
14 Participants
|
4 Participants
|
4 Participants
|
11 Participants
|
8 Participants
|
12 Participants
|
8 Participants
|
29 Participants
|
3 Participants
|
4 Participants
|
9 Participants
|
|
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
Any Treatment Emergent AE
|
14 Participants
|
4 Participants
|
4 Participants
|
11 Participants
|
8 Participants
|
12 Participants
|
8 Participants
|
29 Participants
|
3 Participants
|
4 Participants
|
9 Participants
|
|
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
Drug Related TEAE
|
11 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
5 Participants
|
10 Participants
|
7 Participants
|
24 Participants
|
1 Participants
|
1 Participants
|
8 Participants
|
|
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
Any Serious TEAE
|
6 Participants
|
1 Participants
|
1 Participants
|
4 Participants
|
3 Participants
|
4 Participants
|
3 Participants
|
13 Participants
|
2 Participants
|
2 Participants
|
2 Participants
|
|
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
TEAE Leading to Discontinuation of study drug
|
4 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
5 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
|
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
Hospitalization or Prolongation of Existing Hospitalization
|
6 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
2 Participants
|
3 Participants
|
1 Participants
|
11 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
|
Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event
Death
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
PRIMARY outcome
Timeframe: Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-symptomatic burden were annotated as clinical improvement, anemia response, spleen response, orsymptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The objective response was defined as the number of patients with confirmed complete remission (CR) + partial response (PR) + clinical improvement (CI) during the treatment period.
Outcome measures
| Measure |
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=12 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 2: Number of Patient With Objective Response Using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN)
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
|
—
|
—
|
PRIMARY outcome
Timeframe: From Baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Change from baseline in spleen size was assessed by magnetic resonance imaging (MRI) (computed tomography \[CT\] scan for patients not able to tolerate MRI).
Outcome measures
| Measure |
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=16 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Spleen Size
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-335918.1 cubic millimeter (mm3)
Standard Deviation 558459.9
|
—
|
—
|
PRIMARY outcome
Timeframe: From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Bone marrow was assessed by aspiration and biopsy for grade changes in osteomyelofibrosis. Fibrosis was graded according to European Consensus Myelofibrosis Grading Criteria, ranging from grade 0, which corresponds to normal bone marrow, to grade 3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.
Outcome measures
| Measure |
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=3 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Bone Marrow Assessment
Increased by at least 1 grade level
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
1 Participants
|
—
|
—
|
|
Part 2: Change From Baseline in Bone Marrow Assessment
Increased by at least 2 grade level
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
—
|
—
|
|
Part 2: Change From Baseline in Bone Marrow Assessment
Decreased by at least 1 grade level
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
2 Participants
|
—
|
—
|
|
Part 2: Change From Baseline in Bone Marrow Assessment
Decreased by at least 2 grade level
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0 Participants
|
—
|
—
|
SECONDARY outcome
Timeframe: Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Patients can appear in more than one dose-level cohort. For 300 mg QD, data from 7 patients were available. 4 patients were enrolled originally and 2 patients were dose-reduced from 400 mg QD and 1 patient was dose-reduced from 250 mg BID.
Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-symptomatic burden were annotated as clinical improvement, anemia response, spleen response, orsymptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The objective response was defined as the number of patients with confirmed "complete remission (CR) + partial response (PR) + clinical improvement (CI)" during the treatment period.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=7 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=3 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=3 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=1 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=3 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=2 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1: Number of Patients With Objective Response Using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
|
2 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: From Baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Patients can appear in more than one dose-level cohort. At 200 mg BID cohort, 3 patients were enrolled originally, 2 patients were dose-escalated from 100 mg BID cohort and 8 patients were dose-reduced from 300 mg BID or 400 mg BID cohort.
Change from baseline in spleen size was assessed by palpation.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=6 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=3 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=13 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=1 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=3 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=2 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Spleen Size
|
-3.17 cm
Standard Deviation 3.97
|
—
|
-3.00 cm
Standard Deviation 3.00
|
-4.33 cm
Standard Deviation 6.66
|
-7.00 cm
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
-2.00 cm
Standard Deviation 3.00
|
—
|
—
|
—
|
-0.67 cm
Standard Deviation 2.89
|
-8.25 cm
Standard Deviation 3.18
|
SECONDARY outcome
Timeframe: From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Bone marrow was assessed by aspiration and biopsy for grade changes in osteomyelofibrosis. Fibrosis was graded according to European Consensus Myelofibrosis Grading Criteria, ranging from grade 0, which corresponds to normal bone marrow, to grade 3, in which coarse bundles of collagen fibrosis are identifiable with significant osteosclerosis.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=4 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=1 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=2 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=1 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Bone Marrow Assessment
Increased by at least 1 grade level
|
1 Participants
|
—
|
1 Participants
|
—
|
—
|
2 Participants
|
—
|
—
|
—
|
0 Participants
|
—
|
|
Part 1: Change From Baseline in Bone Marrow Assessment
Increased by at least 2 grade level
|
0 Participants
|
—
|
0 Participants
|
—
|
—
|
0 Participants
|
—
|
—
|
—
|
0 Participants
|
—
|
|
Part 1: Change From Baseline in Bone Marrow Assessment
Decreased by at least 1 grade level
|
3 Participants
|
—
|
0 Participants
|
—
|
—
|
0 Participants
|
—
|
—
|
—
|
1 Participants
|
—
|
|
Part 1: Change From Baseline in Bone Marrow Assessment
Decreased by at least 2 grade level
|
0 Participants
|
—
|
0 Participants
|
—
|
—
|
0 Participants
|
—
|
—
|
—
|
0 Participants
|
—
|
SECONDARY outcome
Timeframe: From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Patients can appear in more than one dose-level cohort. For 300 mg QD, data from 7 patients were available. 4 patients were enrolled originally and 2 patients were dose-reduced from 400 mg QD and 1 patient was dose-reduced from 250 mg BID.
MF SAF is a 20-item instrument comprised of 4 subscales: 1) the Brief Fatigue Inventory \[= average of 9 fatigue scores\], 2) Splenomegaly associated symptoms \[= average of 4 splenomegaly and associated scores\], 3) Catabolic/proliferative Symptoms \[= average of 3 catabolic/proliferative associated scores\] and 4) Overall Quality of Life. The items were on a scale from 1 to 10 where 1= most favorable, and 10= least favorable.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=7 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=3 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=2 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=1 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=3 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=2 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1: Change From Baseline in Quality of Life Assessments Using Myelofibrosis Symptom Assessment Form (MF-SAF)
Overall Quality of Life Score
|
0.0 score on a scale
Standard Deviation 3.6
|
—
|
-1.7 score on a scale
Standard Deviation 2.1
|
-1.5 score on a scale
Standard Deviation 2.1
|
0.0 score on a scale
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
-1.7 score on a scale
Standard Deviation 1.5
|
—
|
—
|
—
|
0.3 score on a scale
Standard Deviation 0.6
|
-1.0 score on a scale
Standard Deviation 1.4
|
|
Part 1: Change From Baseline in Quality of Life Assessments Using Myelofibrosis Symptom Assessment Form (MF-SAF)
Catabolic/Proliferative Symptoms Score
|
-0.4 score on a scale
Standard Deviation 2.4
|
—
|
-0.4 score on a scale
Standard Deviation 1.0
|
1.5 score on a scale
Standard Deviation 1.6
|
-8.0 score on a scale
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
-0.6 score on a scale
Standard Deviation 1.0
|
—
|
—
|
—
|
1.2 score on a scale
Standard Deviation 0.2
|
-0.7 score on a scale
Standard Deviation 0.5
|
|
Part 1: Change From Baseline in Quality of Life Assessments Using Myelofibrosis Symptom Assessment Form (MF-SAF)
Brief Fatigue Inventory Score
|
0.8 score on a scale
Standard Deviation 1.3
|
—
|
-1.9 score on a scale
Standard Deviation 0.1
|
0.4 score on a scale
Standard Deviation 0.2
|
0.7 score on a scale
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
-0.8 score on a scale
Standard Deviation 1.1
|
—
|
—
|
—
|
0.1 score on a scale
Standard Deviation 0.4
|
-1.3 score on a scale
Standard Deviation 2.0
|
|
Part 1: Change From Baseline in Quality of Life Assessments Using Myelofibrosis Symptom Assessment Form (MF-SAF)
Splenomegaly-associated Symptom Score
|
0.5 score on a scale
Standard Deviation 0.8
|
—
|
-0.3 score on a scale
Standard Deviation 1.8
|
-1.1 score on a scale
Standard Deviation 1.2
|
-4.0 score on a scale
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
-1.8 score on a scale
Standard Deviation 1.5
|
—
|
—
|
—
|
1.3 score on a scale
Standard Deviation 1.3
|
-0.5 score on a scale
Standard Deviation 1.1
|
SECONDARY outcome
Timeframe: From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The efficacy population included all patients who received at least one dose of study drug and had one baseline and at least one post-baseline efficacy assessment. Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
Symptoms are evaluated by the MPN-SAF Total Symptom Score (TSS). The MPN-SAF TSS is assessed by the patients themselves and this includes fatigue, concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers. Scoring is from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be) for each item. The MPN-SAF TSS is the summation of all the individual scores (0-100 scale). Symptoms response requires \>50% reduction in the MPN-SAF TSS.
Outcome measures
| Measure |
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=10 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Quality of Life Assessments Using Myeloproliferative Neoplasm Symptom Assessment Form (MPN SAF (MPN 10)
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-0.7 score on a scale
Standard Deviation 3.4
|
—
|
—
|
SECONDARY outcome
Timeframe: Part 1 and Part 2: From baseline to Cycle 7 Day 1 (duration of cycle was 4 weeks)Population: The PD population included all patients who received at least one dose of study drug and had a baseline and at least one post-baseline PD assessment (for at least one PD parameter). Here, the overall number of subjects analyzed signifies only the subjects with available data that were analyzed evaluated on that specific cycle day.
The JAK2 V617F allele burden mean changes from baseline (%) are presented as pharmacodynamics parameters.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=2 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=2 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=2 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=2 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=2 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=4 Participants
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=11 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=1 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=1 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1 and Part 2: Change in Baseline in Janus Kinase 2 (JAK2) V617F Allele Burden Levels
|
7.410 Percentage of JAK2 V617F Level
Standard Deviation 2.758
|
—
|
-6.720 Percentage of JAK2 V617F Level
Standard Deviation 10.479
|
8.255 Percentage of JAK2 V617F Level
Standard Deviation 4.320
|
-4.900 Percentage of JAK2 V617F Level
Standard Deviation 9.065
|
-9.033 Percentage of JAK2 V617F Level
Standard Deviation 5.352
|
-4.368 Percentage of JAK2 V617F Level
Standard Deviation 14.602
|
1.782 Percentage of JAK2 V617F Level
Standard Deviation 8.978
|
—
|
4.360 Percentage of JAK2 V617F Level
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
-0.210 Percentage of JAK2 V617F Level
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
SECONDARY outcome
Timeframe: From Baseline to Pre-dose at Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 (duration of cycle was 4 weeks)Population: The PD population included all patients who received at least one dose of study drug and had a baseline and at least one post-baseline PD assessment (for at least one PD parameter). Here, number analyzed reflects number of patients evaluated on that specific cycle day. Data from 17 out of 24 participants were available and contributed to the analysis. Samples from 7 patients were analyzed, but data were not available due to quantities not sufficient.
The Phospho-STAT3 mean changes from baseline (%) are presented as pharmacodynamics parameters. For phospho-STAT3 values (Phase 2 only), study samples were incubated (± IL-6) and labeled with CD markers. Surface markers included CD3+ (CD4+ \[helper T cells\] and CD8+ \[cytotoxic T cells\]) and CD14+ (monocytes) to which intracellular phospho STAT3 was targeted. The levels of phospho-STAT3 in CD14+, CD3+CD4+ and CD3+CD8+ cell subtypes were quantified. Phosphorylated-STAT3 levels were evaluated in the cell types before and after IL-6 incubation (stimulation) and reported both as mean fluorescence intensity (MFI) and the percentage of positive cells. For each sample time point, the MFI was normalized to a fold change. The fold change was calculated by MFI after IL-6 treatment/MFI before IL-6 treatment. The percent positive cells were normalized by subtracting the percent positive cells before IL-6 treatment from the percent positive cells after IL-6 treatment.
Outcome measures
| Measure |
Part 1: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=24 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 1 Day 1: Change percentage of Phospho-STAT3 Levels in CD14+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-9.406 Percentage of Phospho-STAT 3 Levels
Standard Deviation 19.357
|
—
|
—
|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 1 Day 15: Change percentage of Phospho-STAT3 Levels in CD14+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-2.738 Percentage of Phospho-STAT 3 Levels
Standard Deviation 16.191
|
—
|
—
|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 2 Day 1: Change percentage of Phospho-STAT3 Levels in CD14+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-0.422 Percentage of Phospho-STAT 3 Levels
Standard Deviation 20.092
|
—
|
—
|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 1 Day 1: Change percentage of Phospho-STAT3 Levels in CD3+ CD4+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-10.614 Percentage of Phospho-STAT 3 Levels
Standard Deviation 11.178
|
—
|
—
|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 1 Day 15: Change percentage of Phospho-STAT3 Levels in CD3+ CD4+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
6.217 Percentage of Phospho-STAT 3 Levels
Standard Deviation 20.717
|
—
|
—
|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 2 Day 1: Change percentage of Phospho-STAT3 Levels in CD3+ CD4+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-5.878 Percentage of Phospho-STAT 3 Levels
Standard Deviation 16.304
|
—
|
—
|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 1 Day 1: Change percentage of Phospho-STAT3 Levels in CD3+ CD8+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-3.707 Percentage of Phospho-STAT 3 Levels
Standard Deviation 11.222
|
—
|
—
|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 1 Day 15: Change percentage of Phospho-STAT3 Levels in CD3+ CD8+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
5.533 Percentage of Phospho-STAT 3 Levels
Standard Deviation 14.513
|
—
|
—
|
|
Part 2: Change From Baseline in Phosphorylated Signal Transducer and Activator of Transcription 3 (Phospho-STAT3)
Cycle 2 Day 1: Change percentage of Phospho-STAT3 Levels in CD3+ CD8+ Positive cells
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-1.644 Percentage of Phospho-STAT 3 Levels
Standard Deviation 6.615
|
—
|
—
|
SECONDARY outcome
Timeframe: Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 (duration of cycle was 4 weeks)Population: The PK population include all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile, Here, number analyzed reflects number of patients evaluated on that specific cycle day. Part 2: 1 patient was completely excluded from PK Population due to critical samples missing, 1 patient was excluded from the analysis due to sample missing at timepoint, So the overall number of participants was 27.
To determine the Cmax as pharmacokinetic parameters of NS-018.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=6 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=3 Participants
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=3 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=3 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=6 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=8 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=8 Participants
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=27 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=3 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=3 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part1 and Part 2: Observed Maximum Concentration (Cmax)
Cycle 1 Day 1
|
726.0667 nanogram/milliliter (ng/mL)
Standard Deviation 232.0338
|
1643.0333 nanogram/milliliter (ng/mL)
Standard Deviation 789.0036
|
242.0333 nanogram/milliliter (ng/mL)
Standard Deviation 174.3374
|
351.0000 nanogram/milliliter (ng/mL)
Standard Deviation 257.1729
|
853.5833 nanogram/milliliter (ng/mL)
Standard Deviation 271.7900
|
1077.4750 nanogram/milliliter (ng/mL)
Standard Deviation 366.9158
|
1261.7000 nanogram/milliliter (ng/mL)
Standard Deviation 658.9141
|
957.9852 nanogram/milliliter (ng/mL)
Standard Deviation 306.7937
|
66.5600 nanogram/milliliter (ng/mL)
Standard Deviation 79.0171
|
404.5333 nanogram/milliliter (ng/mL)
Standard Deviation 26.4258
|
377.8000 nanogram/milliliter (ng/mL)
Standard Deviation 184.2086
|
|
Part1 and Part 2: Observed Maximum Concentration (Cmax)
Cycle 1 Day 8 (Part 1 only)
|
805.4333 nanogram/milliliter (ng/mL)
Standard Deviation 236.8877
|
1554.6667 nanogram/milliliter (ng/mL)
Standard Deviation 351.6765
|
412.8000 nanogram/milliliter (ng/mL)
Standard Deviation 232.9342
|
606.8333 nanogram/milliliter (ng/mL)
Standard Deviation 233.7812
|
806.8333 nanogram/milliliter (ng/mL)
Standard Deviation 464.3206
|
969.0167 nanogram/milliliter (ng/mL)
Standard Deviation 342.3090
|
1352.2200 nanogram/milliliter (ng/mL)
Standard Deviation 307.1358
|
—
|
30.6700 nanogram/milliliter (ng/mL)
Standard Deviation 13.3077
|
324.8667 nanogram/milliliter (ng/mL)
Standard Deviation 57.3280
|
539.6667 nanogram/milliliter (ng/mL)
Standard Deviation 160.0954
|
|
Part1 and Part 2: Observed Maximum Concentration (Cmax)
Cycle 1 Day 15 (Part 2 only)
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
732.5000 nanogram/milliliter (ng/mL)
Standard Deviation 313.5822
|
—
|
—
|
—
|
|
Part1 and Part 2: Observed Maximum Concentration (Cmax)
Cycle 2 Day 1
|
1066.0000 nanogram/milliliter (ng/mL)
Standard Deviation 271.1854
|
1556.0000 nanogram/milliliter (ng/mL)
Standard Deviation 676.3941
|
408.6000 nanogram/milliliter (ng/mL)
Standard Deviation 127.0765
|
596.1333 nanogram/milliliter (ng/mL)
Standard Deviation 362.6751
|
830.7333 nanogram/milliliter (ng/mL)
Standard Deviation 166.0701
|
1272.5600 nanogram/milliliter (ng/mL)
Standard Deviation 420.7722
|
1040.6500 nanogram/milliliter (ng/mL)
Standard Deviation 321.5215
|
1035.3087 nanogram/milliliter (ng/mL)
Standard Deviation 445.9895
|
67.6467 nanogram/milliliter (ng/mL)
Standard Deviation 55.6250
|
450.6667 nanogram/milliliter (ng/mL)
Standard Deviation 187.4735
|
556.9000 nanogram/milliliter (ng/mL)
Standard Deviation 52.8463
|
SECONDARY outcome
Timeframe: Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 2 Day 1 (duration of cycle was 4 weeks)Population: The PK population include all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile, Here, number analyzed reflects number of patients evaluated on that specific cycle day. Part 2: 1 patient was completely excluded from PK Population due to critical samples missing, 1 patient was excluded from the analysis due to sample missing at timepoint, So the overall number of participants was 27.
To determine the Tmax as pharmacokinetic parameters of NS-018.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=6 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=3 Participants
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=3 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=3 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=6 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=8 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=8 Participants
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=27 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=3 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=3 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1 and Part 2: Time to Maximum Plasma Concentration (Tmax)
Cycle 1 Day 1
|
1.04 hours (h)
Interval 1.0 to 2.0
|
1.00 hours (h)
Interval 1.0 to 2.0
|
1.00 hours (h)
Interval 1.0 to 1.08
|
1.00 hours (h)
Interval 1.0 to 1.0
|
1.46 hours (h)
Interval 1.0 to 2.13
|
1.02 hours (h)
Interval 1.0 to 23.58
|
2.00 hours (h)
Interval 1.0 to 6.0
|
2.00 hours (h)
Interval 0.92 to 3.0
|
1.00 hours (h)
Interval 0.92 to 2.0
|
1.08 hours (h)
Interval 1.0 to 2.0
|
2.00 hours (h)
Interval 1.0 to 2.17
|
|
Part 1 and Part 2: Time to Maximum Plasma Concentration (Tmax)
Cycle 1 Day 8 (Part 1 only)
|
1.54 hours (h)
Interval 1.02 to 2.25
|
2.00 hours (h)
Interval 1.0 to 2.05
|
1.00 hours (h)
Interval 0.5 to 1.08
|
1.00 hours (h)
Interval 0.5 to 1.02
|
1.98 hours (h)
Interval 1.0 to 3.0
|
1.52 hours (h)
Interval 0.83 to 4.42
|
2.03 hours (h)
Interval 2.0 to 4.0
|
—
|
0.78 hours (h)
Interval 0.5 to 1.05
|
1.00 hours (h)
Interval 1.0 to 1.12
|
1.00 hours (h)
Interval 1.0 to 2.0
|
|
Part 1 and Part 2: Time to Maximum Plasma Concentration (Tmax)
Cycle 2 Day 1
|
1.05 hours (h)
Interval 0.83 to 2.0
|
1.00 hours (h)
Interval 0.82 to 1.02
|
1.00 hours (h)
Interval 0.53 to 1.0
|
1.00 hours (h)
Interval 1.0 to 2.08
|
2.07 hours (h)
Interval 1.0 to 4.0
|
2.08 hours (h)
Interval 1.0 to 5.53
|
2.00 hours (h)
Interval 1.0 to 3.0
|
1.08 hours (h)
Interval 0.92 to 3.0
|
1.00 hours (h)
Interval 1.0 to 2.05
|
1.00 hours (h)
Interval 1.0 to 2.03
|
1.00 hours (h)
Interval 1.0 to 1.0
|
SECONDARY outcome
Timeframe: Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1 (duration of cycle was 4 weeks)Population: The PK Population includes all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile, regardless of whether derived from parent drug or metabolites. Part 2: One patient was completely excluded from the PK Population due to critical samples missing; Two patients were excluded from the analysis due to sample missing at time point. so the overall number of participants analyzed was 26.
To determine the AUC0-24 as pharmacokinetic parameters of NS-018.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=5 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=3 Participants
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=3 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=3 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=4 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=8 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=7 Participants
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=26 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=3 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=3 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part1 and Part 2: Area Under the Plasma Concentration-time Curve (AUC0-24)
Cycle 1 Day 1
|
2299.2216 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 877.2554
|
5162.4119 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 2485.9489
|
1022.0977 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 521.6626
|
1241.5005 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 461.6010
|
2117.1396 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 449.2456
|
5666.7063 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 5182.5571
|
7592.4070 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 3031.4332
|
3672.2041 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 1551.7435
|
246.3454 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 325.7347
|
1510.0507 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 123.2939
|
1326.3929 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 815.0175
|
|
Part1 and Part 2: Area Under the Plasma Concentration-time Curve (AUC0-24)
Cycle 2 Day 1 (Part 1 only)
|
3175.6938 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 794.6091
|
5443.2874 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 986.8497
|
1561.1245 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 621.5414
|
3470.6269 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 2587.3663
|
5876.1106 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 5133.4208
|
6132.2596 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 3393.0644
|
3828.0995 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
—
|
253.6953 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 306.7728
|
1905.2058 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 938.2984
|
1816.8251 hour*nanogram/milliliter (h*ng/mL)
Standard Deviation 559.9071
|
SECONDARY outcome
Timeframe: Pre-dose, 0.5 to 24 hours post-dose for Part 1: Cycle 1 Day 1, Cycle 1 Day 8, Cycle 2 Day 1 and for Part 2: Cycle 1 Day 1, Cycle 2 Day 1 (duration of cycle was 4 weeks)Population: The PK population include all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile, Here, number analyzed reflects number of patients evaluated on that specific cycle day. Part 2: 1 patient was completely excluded from PK Population due to critical samples missing, 1 patient was excluded from the analysis due to sample missing at timepoint, So the overall number of participants was 27.
To determine the t½ as pharmacokinetic parameters of NS-018.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=6 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=3 Participants
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=3 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=3 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=6 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=7 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=7 Participants
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=27 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=3 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=3 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part 1 and Part 2: Terminal Elimination Half-life (t½)
Cycle 1 Day 1
|
4.4899 hour (h)
Standard Deviation 1.5478
|
6.0302 hour (h)
Standard Deviation 2.4730
|
9.7153 hour (h)
Standard Deviation 5.2865
|
10.0780 hour (h)
Standard Deviation 1.3932
|
5.9468 hour (h)
Standard Deviation 3.8500
|
30.0521 hour (h)
Standard Deviation 42.0129
|
13.4566 hour (h)
Standard Deviation 7.3992
|
5.4384 hour (h)
Standard Deviation 1.7469
|
2.4878 hour (h)
Standard Deviation 2.1008
|
5.1659 hour (h)
Standard Deviation 0.5209
|
3.6685 hour (h)
Standard Deviation 2.2953
|
|
Part 1 and Part 2: Terminal Elimination Half-life (t½)
Cycle 1 Day 8 (Part 1 only)
|
2.6237 hour (h)
Standard Deviation 0.5050
|
2.8480 hour (h)
Standard Deviation 1.3889
|
2.3007 hour (h)
Standard Deviation 0.0899
|
3.5204 hour (h)
Standard Deviation 1.6584
|
2.6280 hour (h)
Standard Deviation 0.8577
|
3.2062 hour (h)
Standard Deviation 0.8054
|
2.8287 hour (h)
Standard Deviation 1.2416
|
—
|
1.9170 hour (h)
Standard Deviation 0.5066
|
2.4735 hour (h)
Standard Deviation 0.3469
|
2.0217 hour (h)
Standard Deviation 0.2653
|
|
Part 1 and Part 2: Terminal Elimination Half-life (t½)
Cycle 2 Day 1
|
5.9316 hour (h)
Standard Deviation 0.8500
|
8.5232 hour (h)
Standard Deviation 5.0118
|
16.5535 hour (h)
Standard Deviation 6.8417
|
8.7138 hour (h)
Standard Deviation 6.8781
|
10.8357 hour (h)
Standard Deviation 1.0282
|
13.7574 hour (h)
Standard Deviation 8.1372
|
7.7683 hour (h)
Standard Deviation 5.3755
|
2.8030 hour (h)
Standard Deviation 1.2594
|
3.7488 hour (h)
Standard Deviation 2.9554
|
5.6743 hour (h)
Standard Deviation 1.3845
|
5.4356 hour (h)
Standard Deviation 0.7253
|
SECONDARY outcome
Timeframe: Part 1 and Part 2: Cycle 2 Day 1 (duration of cycle was 4 weeks)Population: The PK Population includes all patients who received at least one dose of study drug and have at least 50% of the planned samples above the limit of quantitation to provide evaluable PK profile (i.e. at least Cmax and AUC evaluable), regardless of whether derived from parent drug or metabolites.
To determine the AR as pharmacokinetic parameters of NS-018. AR was calculated as AR = (AUC0-24) Cycle 2 Day 1/ (AUC0-24) Cycle 1 Day 1.
Outcome measures
| Measure |
Part 1: 300 mg QD
n=4 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=3 Participants
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=2 Participants
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=2 Participants
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=3 Participants
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=3 Participants
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=1 Participants
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=22 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=1 Participants
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=3 Participants
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=2 Participants
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Part1 and Part 2: Accumulation Ratio (AR)
|
1.3581 Ratio
Standard Deviation 0.3108
|
1.2026 Ratio
Standard Deviation 0.4755
|
1.9941 Ratio
Standard Deviation 0.6140
|
3.3229 Ratio
Standard Deviation 0.3197
|
3.0501 Ratio
Standard Deviation 2.6306
|
1.5452 Ratio
Standard Deviation 0.4025
|
1.2514 Ratio
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
1.0543 Ratio
Standard Deviation 0.2572
|
0.9778 Ratio
Standard Deviation NA
As only 1 participant was evaluable, hence SD is not calculable.
|
1.2517 Ratio
Standard Deviation 0.5579
|
1.1728 Ratio
Standard Deviation 0.0372
|
Adverse Events
Part 1: 75 mg QD
Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths
Part 1: 125 mg QD
Serious events: 2 serious events
Other events: 4 other events
Deaths: 0 deaths
Part 1: 200 mg QD
Serious events: 2 serious events
Other events: 9 other events
Deaths: 0 deaths
Part 1: 300 mg QD
Serious events: 6 serious events
Other events: 14 other events
Deaths: 0 deaths
Part 1: 400 mg QD
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
Part 1: 100 mg BID
Serious events: 1 serious events
Other events: 4 other events
Deaths: 0 deaths
Part 1: 200 mg BID
Serious events: 4 serious events
Other events: 11 other events
Deaths: 0 deaths
Part 1: 250 mg BID
Serious events: 3 serious events
Other events: 8 other events
Deaths: 0 deaths
Part 1: 300 mg BID
Serious events: 4 serious events
Other events: 12 other events
Deaths: 0 deaths
Part 1: 400 mg BID
Serious events: 3 serious events
Other events: 7 other events
Deaths: 0 deaths
Part 2: 300 mg QD
Serious events: 13 serious events
Other events: 29 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
Part 1: 75 mg QD
n=3 participants at risk
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=4 participants at risk
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=10 participants at risk
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg QD
n=15 participants at risk
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=4 participants at risk
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=5 participants at risk
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=13 participants at risk
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=8 participants at risk
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=12 participants at risk
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=8 participants at risk
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=29 participants at risk
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Appendicitis perforated
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Arthritis infective
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Influenza
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Haemolysis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Haemolytic anaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Splenic infarction
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Splenomegaly
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Seizure
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Syncope
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Lung infiltration
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Acute coronary syndrome
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Coronary artery occlusion
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Sinus node dysfunction
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Chest pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Generalised oedema
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Spinal stenosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Steroid diabetes
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Tumour lysis syndrome
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma multiforme
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Suicide attempt
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Hepatobiliary disorders
Hepatosplenomegaly
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Postoperative ileus
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Lipase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Acute sinusitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Otitis externa
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Otitis media
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Parainfluenzae virus infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Vulval cellulitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Left ventricular failure
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Cardiac failure acute
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Haematoma muscle
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Mallory-Weiss syndrome
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
N-terminal prohormone brain natriuretic peptide increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
Other adverse events
| Measure |
Part 1: 75 mg QD
n=3 participants at risk
Patients self-administered orally 75 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 125 mg QD
n=4 participants at risk
Patients self-administered orally 125 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg QD
n=10 participants at risk
Patients self-administered orally 200 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg QD
n=15 participants at risk
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg QD
n=4 participants at risk
Patients self-administered orally 400 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 100 mg BID
n=5 participants at risk
Patients self-administered orally 100 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 200 mg BID
n=13 participants at risk
Patients self-administered orally 200 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 250 mg BID
n=8 participants at risk
Patients self-administered orally 250 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 300 mg BID
n=12 participants at risk
Patients self-administered orally 300 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 1: 400 mg BID
n=8 participants at risk
Patients self-administered orally 400 mg of NS-018 twice daily (BID) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
Part 2: 300 mg QD
n=29 participants at risk
Patients self-administered orally 300 mg of NS-018 once daily (QD) in cycles of 28 days in duration (4 weeks) for Cycles 1, 2, 3, 4, 5, 6, 7 and until the patient experiences unacceptable toxicity that precludes any further treatment, disease progression, and/or as long as the patient is benefiting from treatment.
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Rales
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-airway cough syndrome
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Pregnancy, puerperium and perinatal conditions
Pelvic girdle pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Fatigue
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
6/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
2/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
23.1%
3/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
4/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.9%
11/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Oedema peripheral
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
2/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
5/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
2/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
34.5%
10/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Pyrexia
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Chills
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Chest discomfort
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Influenza like illness
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Asthenia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Early satiety
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Gait disturbance
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Oedema
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Thirst
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Adverse drug reaction
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Chest pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Cyst
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Drug withdrawal syndrome
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Face oedema
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Generalised oedema
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Localised oedema
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Malaise
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Nodule
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
General disorders
Peripheral swelling
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
50.0%
2/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
2/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
24.1%
7/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
23.1%
3/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
5/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
17.2%
5/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
17.2%
5/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Chondrocalcinosis pyrophosphate
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Fibromyalgia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Joint effusion
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Limb discomfort
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Soft tissue mass
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Spinal stenosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
5/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
50.0%
2/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
2/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
23.1%
3/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.5%
3/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
50.0%
6/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
27.6%
8/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Headache
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
26.7%
4/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
41.7%
5/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.9%
11/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
50.0%
2/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Balance disorder
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Disturbance in attention
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Dizziness postural
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Aphasia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Ataxia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Dysaesthesia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Dysarthria
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Lethargy
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Migraine
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Muscle contractions involuntary
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Sciatica
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Sensory disturbance
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Nervous system disorders
Tremor
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Anaemia
|
66.7%
2/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
4/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
2/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
38.5%
5/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
50.0%
6/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.5%
3/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
41.4%
12/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.5%
3/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
3/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Increased tendency to bruise
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Hypoprothrombinaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
30.8%
4/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
24.1%
7/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hyperphosphataemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hyperlipidaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hypermagnesaemia
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Iron deficiency
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Steroid diabetes
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Fluid overload
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
2/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
5/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
2/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Oral candidiasis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Influenza
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Acute sinusitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Body tinea
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Ear infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Fungal infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Genital abscess
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Hordeolum
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Infected seroma
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Lip infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Localised infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Molluscum contagiosum
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Otitis media
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Rectal abscess
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Rhinovirus infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Skin infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Subcutaneous abscess
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blood uric acid increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Tinea pedis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Infections and infestations
Wound infection
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
2/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Macule
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Rash pruritic
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Madarosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Neurodermatitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Emotional distress
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Onychoclasis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Rash erythematous
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Actinic keratosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Muscle strain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
2/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Animal bite
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Animal scratch
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Foreign body
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Incision site pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Ligament injury
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blood urea increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Sleep terror
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Skin abrasion
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Skin wound
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
50.0%
4/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Depressed mood
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Mental disorder
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Alcohol withdrawal syndrome
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Serum ferritin increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blast cell count increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Claustrophobia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
30.0%
3/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
6/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
23.1%
3/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
4/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.5%
3/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.9%
11/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
2/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.5%
3/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
58.3%
7/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
34.5%
10/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
37.5%
3/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
4/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
27.6%
8/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
41.7%
5/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.7%
6/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Anal pruritus
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Anal sphincter atony
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Haematochezia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Hypoaesthesia oral
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Oesophageal ulcer
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Oral discomfort
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blood cholesterol increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Platelet count decreased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Weight increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
2/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
White blood cell count decreased
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Amylase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Electrocardiogram QT prolonged
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.8%
4/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blood potassium increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Cardiac murmur
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Lipase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Neutrophil count decreased
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Physical examination abnormal
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Heart rate abnormal
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Red blood cell count increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Troponin I increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Vitamin B1 decreased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
White blood cell count increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Blood lactate dehydrogenase increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
5/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
30.8%
4/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
50.0%
4/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
3/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
24.1%
7/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
2/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
5/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
40.0%
2/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
33.3%
4/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
44.8%
13/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.7%
6/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal inflammation
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Psychiatric disorders
Tobacco withdrawal symptoms
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Chromaturia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Urinary retention
|
33.3%
1/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Pollakiuria
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Renal and urinary disorders
Urinary tract pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
15.4%
2/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
3/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Cardiac flutter
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
13.3%
2/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
16.7%
2/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Vascular disorders
Haematoma
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Vascular disorders
Flushing
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Vascular disorders
Hot flush
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
1/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Vascular disorders
Pallor
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Vascular disorders
Thrombosis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Vision blurred
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Cataract
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Glaucoma
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Blepharitis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Dry eye
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Eye swelling
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Eyelid irritation
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Lacrimation increased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Meibomian gland dysfunction
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Photophobia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Eye disorders
Strabismus
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
25.0%
2/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.3%
3/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
3.4%
1/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Reproductive system and breast disorders
Breast cyst
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
8.3%
1/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Reproductive system and breast disorders
Menorrhagia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Reproductive system and breast disorders
Oedema genital
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Reproductive system and breast disorders
Penis disorder
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone neoplasm
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Muscle neoplasm
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
10.0%
1/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.7%
1/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Hepatobiliary disorders
Hepatic pain
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
12.5%
1/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Hepatobiliary disorders
Hepatomegaly
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
1/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Hepatobiliary disorders
Jaundice
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Investigations
Weight decreased
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
20.0%
3/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
7.7%
1/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/3 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/10 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/15 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/4 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/5 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/13 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/12 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
0.00%
0/8 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
6.9%
2/29 • Part 1 and Part 2: From screening to until study discontinuation (approximate 8 years 10 months)
Safety population: NS-018-101 study was dose finding study, PI could increase or decrease dose-level per protocol. Totals are based on number of patients and not on dose-level cohort. Patients can appear in more than one dose-level cohort.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee This confidential document is the property of NS Pharma, Inc. No unpublished information contained herein may be disclosed without prior written approval from NS Pharma, Inc. Access to this document must be restricted to relevant parties.
- Publication restrictions are in place
Restriction type: OTHER